Request Demo
Last update 15 Feb 2025
Dexrazoxane Hydrochloride
Last update 15 Feb 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms dexrazoxane, Topotect, Totect + [13] |
Target |
Mechanism Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (26 May 1995), |
RegulationAccelerated Approval (US), Orphan Drug (US), Orphan Drug (AU) |
Login to view timeline
Structure/Sequence
Molecular FormulaC11H17ClN4O4 |
InChIKeyBIFMNMPSIYHKDN-FJXQXJEOSA-N |
CAS Registry149003-01-0 |
Related
51
Clinical Trials associated with Dexrazoxane HydrochlorideNCT06647953
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)
NCT06220032
ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label Trial
NCT06262438
A Phase II, Single Arm, Open Label, Study on the Safety, Efficacy, Pharmacokinetics & Pharmacodynamics of Quizartinib + Chemotherapy and as Single-agent After High Dose Therapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
100 Clinical Results associated with Dexrazoxane Hydrochloride
Login to view more data
100 Translational Medicine associated with Dexrazoxane Hydrochloride
Login to view more data
100 Patents (Medical) associated with Dexrazoxane Hydrochloride
Login to view more data
1,224
Literatures (Medical) associated with Dexrazoxane Hydrochloride01 Feb 2025CARDIOLOGY CLINICS
Cardiotoxicity of Anthracyclines
Review
Author: Hoeger, Christopher W. ; Ariza, Abul ; Asnani, Aarti ; Balough, Elizabeth ; Hoeger, Christopher W
Anthracycline chemotherapy is associated with cardiotoxicity, predominantly manifesting as left ventricular systolic dysfunction within the first year of treatment. Early detection is possible through biomarkers and cardiovascular imaging before clinical symptoms develop. Comprehensive cardiovascular risk assessment is essential for all patients prior to anthracycline therapy to stratify their risk of cardiotoxicity. Preventive measures, including cardiovascular risk optimization, as well as anthracycline dose adjustments, the use of liposomal anthracyclines, and dexrazoxane in high-risk patients, are crucial to mitigate the risk of cardiotoxicity. Long-term follow-up and cardiovascular risk optimization are critical for cancer survivors to optimize cardiovascular outcomes.
01 Feb 2025YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
Anthracycline-Induced Cardiotoxicity and Exploration of Cardioprotective Drugs
Review
Author: Hara, Akiyoshi
Many anticancer drugs, including anthracycline drugs, pose a risk of cardiovascular damage as an adverse reaction. This can detrimentally impact the prognosis and quality of life of patients, potentially leading to the interruption of cancer chemotherapy and compromising cancer treatment. Recently, onco-cardiology (or cardio-oncology) has developed as a new interdisciplinary field that focuses on the prevention and treatment of cardiovascular toxicity of anticancer drugs. In this review, we explore the mechanism underlying the cardiotoxicity of anthracyclines and examine pharmacological agents that safeguard the heart from anthracycline-induced damage. Anthracycline-induced cardiotoxicity primarily involves oxidative stress, characterized by radical production in mitochondria and subsequent apoptosis in cardiomyocytes. While various antioxidant agents, such as resveratrol, vitamin E, and melatonin have demonstrated efficacy in reducing anthracycline-induced cardiotoxicity in animal models, their clinical effectiveness remains inconclusive. Alternatively, dexrazoxane, an intracellular iron chelator, along with standard heart failure medications, such as β-blockers, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers, reduce anthracycline cardiotoxicity and prevent subsequent heart failure in both animal and human studies. Additionally, statins [hydroxymethylglutaryl (HMG)-CoA reductase inhibitors] and ranolazine have emerged as potential candidates for attenuating anthracycline-induced cardiotoxicity in clinical settings. Notably, recent in vitro findings suggest that everolimus, an autophagy/mitophagy-inducing antitumor drug, may protect cardiomyocytes from anthracycline-induced toxicity without reducing the antitumor effects of anthracycline. Although promising, further clinical research is warranted to validate the potential of everolimus as a safer and more effective anthracycline chemotherapeutic strategy.
01 Jan 2025Journal of Natural Medicines
Preventive effect of imperatorin against doxorubicin-induced cardiotoxicity through suppression of NLRP3 inflammasome activation
Article
Author: Bao, Huiyun ; Wang, Hu ; Xie, Mengdie ; Zhang, Hao ; Tang, Xilan ; Xiong, Yinhua ; Huang, Si ; Li, Tingting ; Ding, Xiaoyun ; Qiu, Yumei
Cardiotoxicity is one of the major obstacles to anthracycline chemotherapy. Anthracycline cardiotoxicity is closely associated with inflammation. Imperatorin (IMP), a furocoumarin ingredient extracted from Angelica dahurica, might have potential activity in preventing anthracycline cardiotoxicity due to its anti-cancer, anti-inflammatory, anti-oxidant, cardioprotective properties. This study aims to reveal the effect of IMP on doxorubicin (DOX)-induced cardiotoxicity and its underlying mechanism. We established a rat model of DOX-induced cardiotoxicity by intraperitoneal injection with DOX (1.25 mg/kg twice weekly for 6 weeks), and found that both IMP (25 mg/kg and 12.5 mg/kg) and dexrazoxane 12.5 mg/kg relieved DOX-induced reductions in heart weight, change in cardiac histopathology, and elevated serum levels of LDH, AST and CK-MB. Moreover, DOX upregulated mRNA levels of NLRP3, CASP1, GSDMD, ASC, IL-1β and IL-18, elevated protein expressions of NLRP3, ASC, GSDMD-FL, GSDMD-N, pro‑caspase‑1, caspase‑1 p20, pro‑IL‑1β and IL‑1β in heart tissues, as well as increased serum levels of pro-inflammatory cytokines including IL-1β and IL-18, however both of IMP and dexrazoxane suppressed these alterations. In addition, we carried out neonatal rat cardiomyocytes experiments to confirm the results of the in vivo study. Consistently, pretreatment with IMP 25 µg/mL relieved DOX (1 μg/mL)-induced cardiomyocytes injury, including decreased cell viability and reduced supernatant LDH. IMP inhibited DOX-induced activation of NLRP3 inflammasome in cardiomyocytes. In conclusion, IMP had a protective effect against DOX-induced cardiotoxicity via repressing the activation of NLRP3 inflammasome. These findings suggest that IMP may be a promising alternative or adjunctive drug for the prevention of anthracycline cardiotoxicity.
3
News (Medical) associated with Dexrazoxane Hydrochloride11 Aug 2023
AcquisitionLicense out/in
10 Aug 2023
AcquisitionRadiation Therapy
09 Feb 2019
Accelerated ApprovalOrphan DrugFast TrackBreakthrough TherapyDrug Approval
100 Deals associated with Dexrazoxane Hydrochloride
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D07807 | Dexrazoxane Hydrochloride |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Extravasation of Diagnostic and Therapeutic Materials | EU | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | IS | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | LI | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | NO | 27 Jul 2006 | |
| Cytoprotective Agent | CN | 29 May 2006 | |
| Cardiomyopathies | US | 26 May 1995 | |
| Metastatic breast cancer | US | 26 May 1995 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hemorrhage | Phase 3 | DK | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | DE | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | IT | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | NL | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | PL | 01 Apr 2002 | |
| Bronchitis | Phase 3 | DK | 01 Jun 2001 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | ysgoxmkips(uzlzjrmqnt) = mxnzadlwqb ghfsljtflt (armshwywpn ) View more | - | 07 Dec 2024 | |||
Non-initiators of Dexrazoxane | ysgoxmkips(uzlzjrmqnt) = cufhkhmiom ghfsljtflt (armshwywpn ) View more | ||||||
Not Applicable | 142 | Anthracycline + Dexrazoxane | xhjnzgnhyz(gdgrxrpoin) = uqgjkwumsz evhtiswqtt (ctoyrzcrdi ) | Positive | 31 May 2023 | ||
Anthracycline only | xhjnzgnhyz(gdgrxrpoin) = getnqnonzi evhtiswqtt (ctoyrzcrdi ) View more | ||||||
Not Applicable | 263 | nnjuobmthv(xapktoidho) = prgvhfrkkv nvbuzotevz (cxuthaozfz ) View more | - | 03 Dec 2022 | |||
nnjuobmthv(xapktoidho) = khyqvjsyjq nvbuzotevz (cxuthaozfz ) View more | |||||||
Not Applicable | - | 1,308 | Doxorubicin with dexrazoxane | vwtrhbznom(bqaoheqauk): HR = 1.07 (95% CI, 0.78 - 1.47) View more | - | 15 Feb 2022 | |
Doxorubicin without dexrazoxane | |||||||
Phase 3 | 236 | Therapeutic Conventional Surgery (Very Low-risk Group) | putyytzraa(gkiarbwfoz) = wkkjpszfhg fqzgfzzrln (orgyegqavc, hpptgywzfh - jfkmtqkzee) View more | - | 28 Dec 2021 | ||
(Low-risk Group (Regimen T)) | putyytzraa(gkiarbwfoz) = mfzrcjgtfh fqzgfzzrln (orgyegqavc, wvwckuozxn - bmglftkswj) View more | ||||||
Not Applicable | 2,375 | lmbmdpdexd(fjobsryxrp): OR = 1.15 (95% CI, 0.57 - 2.31), P-Value = 0.7 View more | - | 29 Jun 2021 | |||
No drug or placebo | |||||||
Not Applicable | 173 | zqmiqewfgn(yenkmdwilz) = dbdcygwhcl ffxefrhoah (tgocsxqkhi, 6.0 - 18.0) View more | Positive | 25 May 2020 | |||
zqmiqewfgn(yenkmdwilz) = cmiyiqkcok ffxefrhoah (tgocsxqkhi, 6.0 - 28.2) View more | |||||||
Phase 2 | 46 | (Arm A: VACdxr With ImmTher) | ncdhksmjtr(trlacqmrbo) = ifpveluhad iiarwmgqus (cubcdbxqwm, bagsrpmczr - csidiorekm) View more | - | 29 Jan 2020 | ||
(Arm B: VACdxr) | ncdhksmjtr(trlacqmrbo) = zniyrakiqa iiarwmgqus (cubcdbxqwm, aowhomllpg - buzogtjcsk) View more | ||||||
Phase 1 | 1 | xjxpovmhed(fvzlcexuvz) = fhijcsruhb lbqofjmuka (mijfeuxsbb, hlkfussjve - njyhojeafo) View more | - | 19 Feb 2019 | |||
Not Applicable | Breast Cancer Adjuvant | 1,545 | qefznxsokc(vtlnpxogop): RR = 0.262 (95% CI, 0.169 - 0.407) View more | Positive | 01 Jun 2018 | ||
Anthracycline-based chemotherapy |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free